PUBLIC COMPANY
save$KRYSKrystal Biotech, Inc.
$KRYS322.28-0.93%Pittsburgh, PA, USupdated 1d ago
community read0 votes
pipeline
5
marketed
1
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
2Phase 12Phase 21Marketed
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- EP1A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease
- phase3A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
- phase2A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
- phase2A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
- phase1A Study Assessing KB407 for the Treatment of Cystic Fibrosis
- phase1A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
- —A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)
- phase2A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
🐶 Hiring Signal
next earnings Nov 2, 2026
News
- J&J pharma leader to retire; Krystal slumps on gene therapy missJennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.biopharma_dive · 2mo ago
- French gene therapy biotech gets €33M to follow Krystal's blueprintA small French-US biotech has gathered more funds to see if it can follow in the footsteps of Krystal Biotech in the HSV-based gene therapy field, but in a different therapeutic area. Cyllene Thera…endpoints · 2mo ago
Data sources
last refreshed 43m ago
Found something off?
comments(0)
5-min edit window · permanent after that